Rudy Li
Stock Analyst at Wolfe Research
(4.90)
# 214
Out of 4,463 analysts
74
Total ratings
60.3%
Success rate
81.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $33 | $25.20 | +30.95% | 2 | May 6, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $160 | $167.77 | -4.63% | 2 | Apr 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $500 | $319.60 | +56.45% | 7 | Apr 6, 2026 | |
| ALKS Alkermes | Initiated Coverage: Buy | $45 | $51.72 | -12.99% | 2 | Feb 23, 2026 | |
| QURE uniQure | Initiated Coverage: Hold | n/a | $45.17 | - | 1 | Feb 23, 2026 | |
| XENE Xenon Pharmaceuticals | Initiated Coverage: Buy | $55 → $60 | $60.30 | -0.50% | 5 | Feb 23, 2026 | |
| AXSM Axsome Therapeutics | Initiated Coverage: Buy | $230 | $240.66 | -4.43% | 1 | Feb 23, 2026 | |
| DFTX Definium Therapeutics | Initiated Coverage: Buy | $20 → $25 | $43.40 | -42.40% | 11 | Feb 23, 2026 | |
| LON: 0NZT UCB SA | Initiated Coverage: Buy | €340.00 | $262.00 | +29.77% | 1 | Feb 23, 2026 | |
| DNLI Denali Therapeutics | Initiated Coverage: Hold | n/a | $25.98 | - | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 → $40 | $32.71 | +22.29% | 19 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $9.58 | +87.89% | 15 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $14.81 | +102.57% | 2 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $24.94 | -39.86% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $0.657644 | +5,982.32% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $66.54 | n/a | 2 | May 21, 2025 |
ACADIA Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $33
Current: $25.20
Upside: +30.95%
Neurocrine Biosciences
Apr 6, 2026
Reiterated: Buy
Price Target: $160
Current: $167.77
Upside: -4.63%
Praxis Precision Medicines
Apr 6, 2026
Maintained: Buy
Price Target: $500
Current: $319.60
Upside: +56.45%
Alkermes
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $51.72
Upside: -12.99%
uniQure
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $45.17
Upside: -
Xenon Pharmaceuticals
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $55 → $60
Current: $60.30
Upside: -0.50%
Axsome Therapeutics
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $230
Current: $240.66
Upside: -4.43%
Definium Therapeutics
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $20 → $25
Current: $43.40
Upside: -42.40%
UCB SA
Feb 23, 2026
Initiated Coverage: Buy
Price Target: €340.00
Current: $262.00
Upside: +29.77%
Denali Therapeutics
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $25.98
Upside: -
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $24 → $40
Current: $32.71
Upside: +22.29%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $18
Current: $9.58
Upside: +87.89%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $14.81
Upside: +102.57%
Oct 20, 2025
Maintained: Buy
Price Target: $15
Current: $24.94
Upside: -39.86%
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $40
Current: $0.657644
Upside: +5,982.32%
May 21, 2025
Reiterated: Buy
Price Target: $80
Current: $66.54
Upside: n/a